Implantable Hemostatic Device
Intraoperative Bleeding Control
Pre-clinicalActive
Key Facts
About Karamedica
Karamedica is a private, pre-revenue biotech company developing a proprietary non-thermal plasma technology to decontaminate chitosan, a promising but sterilization-sensitive biopolymer derived from crustacean shells. This platform overcomes a major historical barrier, allowing chitosan to be used in implantable medical devices and targeted drug delivery systems. The company's initial pipeline focuses on an implantable hemostatic device for surgery and drug delivery vehicles for superficial bladder cancer and cerebral amyloid angiopathy (CAA), a condition linked to Alzheimer's disease.
View full company profile